Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-16

Study Completion Date

2017-09-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This proposal will evaluate if musculoskeletal ultrasound (MSUS) measures or multi-biomarker disease activity (MBDA) improve in patients treated with tofacitinib over 3 months, and whether early MSUS measures/MBDA can predict response to therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis

NCT02837146

Rheumatoid Arthritis

UNKNOWN PHASE3

Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients

NCT04079920

Rheumatoid Arthritis

COMPLETED

Targeted Ultrasound in Rheumatoid Arthritis

NCT02056184

Rheumatoid Arthritis Targeted Ultrasound

COMPLETED PHASE4

Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica

NCT04799262

Polymyalgia Rheumatica Effect of Drug Safety Issues

COMPLETED PHASE2

The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis

NCT05133297

Rheumatoid Arthritis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a pilot open-label trial of 25 RA patients treated with tofacitinib over 3 months. The patients meeting inclusion criteria will be started on tofacitinib 5mg po bid. Patients will be recruited from the UCLA Rheumatology Clinics. Inclusion criteria will include the following: meeting ACR 1987 RA criteria, DAS28≥3.2, age≥18, and PDUS\>10 (see below for more details). Patients who are deemed unsafe to enroll will be excluded. Ultrasound measures (PDUS/GSUS) and MBDA scores will be obtained at screen, baseline, 2 weeks, and 3 months. In addition, we will also obtain HAQ-DI, CDAI, and DAS28 at the same time points. In addition, we will have a 6 week visit for capturing adverse events, concomitant drugs, drug dispensation, and evaluation of adherence. Currently, there are several US measures to evaluate therapeutic response in RA patients that have been used in the literature. Some US studies evaluate all joints involved in RA, which is time consuming. At present, there is no consensus as to the ideal ultrasound scoring system. However, we will utilize a 34-joint US scoring system to evaluate response to therapy in this proposal (see Table 1). Our research team has expertise in MSUS (given several workshops/lectures nationally) and we have proficiency in designing/conducting MSUS clinical trials. We currently have 4 ultrasonography-rheumatologists at UCLA who are ACR certified in MSUS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

tofacitinib 5mg po bid

Open label with tofacitinib 5mg po bid

Group Type OTHER

tofacitinib 5mg po bid

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tofacitinib 5mg po bid

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient must meet 1987 ACR criteria
2. Age \> 18 years of age
3. Baseline DAS28/ESR\>=3.2
4. Stable concomitant DMARDs
5. Stable prednisone \<10mg or equivalent
6. Power Doppler score of \>=10
7. Female subjects of childbearing potential must test negative for pregnancy
8. Male and female subjects of childbearing potential must agree to use contraception throughout the study
9. Negative QuantiFERON Gold test at screening

Exclusion Criteria

1. No active TB
2. Prednisone \>10 mg
3. Pregnancy or breast feeding
4. Prior treatment with tofacitinib
5. Concomitant biologic therapy (TNF inhibitors, IL-6 inhibitors, etc.)
6. Active infection with HIV, hepatitis B or C, or herpes zoster
7. Subjects with any uncontrolled clinically significant laboratory abnormality or any of the following laboratory abnormalities:

1. Evidence of hematopoietic disorder or hemoglobin \<9 g/dL
2. Absolute lymphocyte count \<0.75 x 109/L (\<750/mm3)
3. Absolute neutrophil count \<1.2 x 109/L (\<1200/mm3)
4. Platelet count \<100 x 109/L (\<100,000/mm3)
5. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) \>1.5 times the upper limit of normal (x ULN)
6. Estimated GFR \<40 ml/min
8. Subjects who have received live or live attenuated vaccines within 6 weeks prior to the first dose of study drug (or the zoster vaccine)
9. Subjects who require concomitant treatment with medications that are potent inhibitors of cytochrome P450 3A4 (CYP3A4), both moderate inhibitors of CYP3A4 and potent inhibitors of CYP2C19, and potent CYP inducers (See Appendix)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No